Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer ; volume:12 ; number:1 ; day:27 ; month:12 ; year:2022 ; pages:1-16 ; date:12.2022
Scientific reports ; 12, Heft 1 (27.12.2022), 1-16, 12.2022
- Urheber
-
Polverino, F.
Mirra, D.
Yang, C. X.
Esposito, R.
Spaziano, G.
Rojas-Quintero, J.
Sgambato, M.
Piegari, E.
Cozzolino, A.
Cione, E.
Gallelli, L.
Capuozzo, A.
Santoriello, C.
Berrino, L.
Torres, J. P. de-
Hackett, T. L.
Polverino, M.
D’Agostino, B.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-022-26650-9
- URN
-
urn:nbn:de:101:1-2023030821150620481751
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Polverino, F.
- Mirra, D.
- Yang, C. X.
- Esposito, R.
- Spaziano, G.
- Rojas-Quintero, J.
- Sgambato, M.
- Piegari, E.
- Cozzolino, A.
- Cione, E.
- Gallelli, L.
- Capuozzo, A.
- Santoriello, C.
- Berrino, L.
- Torres, J. P. de-
- Hackett, T. L.
- Polverino, M.
- D’Agostino, B.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Programmed death-ligand 1 (PD-L1) expression in various tumor types
Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
Regulation des Programmed cell death ligand 1 (PD-L1) auf Phagozyten durch den alternativen Aktivierungsweg des Komplementsystems
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies
Untersuchung des solublen Programmed Cell Death Ligand 1 (sPD-L1) Plasmaspiegels bei Patienten mit paroxysmaler nächtlicher Hämoglobinurie und der Programmed Cell Death Ligand 1 (PD-L1) Expression bei in vitro Komplementaktivierung
Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Programmed death-ligand 1 (PD-L1) expression in various tumor types
Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
Regulation des Programmed cell death ligand 1 (PD-L1) auf Phagozyten durch den alternativen Aktivierungsweg des Komplementsystems
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies
Untersuchung des solublen Programmed Cell Death Ligand 1 (sPD-L1) Plasmaspiegels bei Patienten mit paroxysmaler nächtlicher Hämoglobinurie und der Programmed Cell Death Ligand 1 (PD-L1) Expression bei in vitro Komplementaktivierung
Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Programmed death-ligand 1 (PD-L1) expression in various tumor types
Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
Regulation des Programmed cell death ligand 1 (PD-L1) auf Phagozyten durch den alternativen Aktivierungsweg des Komplementsystems
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies
Untersuchung des solublen Programmed Cell Death Ligand 1 (sPD-L1) Plasmaspiegels bei Patienten mit paroxysmaler nächtlicher Hämoglobinurie und der Programmed Cell Death Ligand 1 (PD-L1) Expression bei in vitro Komplementaktivierung
Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status